Single bolus PCSK9 Inhibition: A new approach to plaque stabilisation
In the current issue of Atherosclerosis, Kataoka and colleagues present the findings of a single-arm study evaluating the impact of a single dose of a PCSK9 inhibitor on coronary atherosclerosis.1 The development of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has transformed the ability to effectively lower levels of low-density lipoprotein cholesterol (LDL-C) in patients at high risk of cardiovascular disease. These benefits have translated to favourable effects on the burden2 and composition3-5 of coronary atherosclerosis and a reduction in cardiovascular event rates in large clinical outcome trials6, 7.
